0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Viewpoint |

The Story of Glutamate in Drug Addiction and of N-Acetylcysteine as a Potential Pharmacotherapy

Robyn M. Brown, PhD1,2; Yonatan M. Kupchik, PhD1; Peter W. Kalivas, PhD1
[+] Author Affiliations
1Department of Neurosciences, Medical University of South Carolina, Charleston, South Carolina
2Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Australia
JAMA Psychiatry. 2013;70(9):895-897. doi:10.1001/jamapsychiatry.2013.2207.
Text Size: A A A
Published online

Extract

The prevalence and impact of drug addiction on society are staggering. The abuse of alcohol, tobacco, and illicit drugs accounts for approximately 10% of the global burden of disease, and for the United States, it is estimated that substance use disorders affect 20.4 million individuals.1 Despite the deleterious economic and social consequences of drug use, approved medications to treat substance use disorders are few or absent depending on the drug. We and others have explored the possibility that dysregulation in prefrontal and allocortical (amygdala and hippocampus) glutamatergic inputs to the basal ganglia may be a mechanism responsible for relapse that is shared between classes of addictive drugs, as well as other disorders characterized by maladaptive compulsive behavior. Herein, we describe the bench-to-bedside chronology of preclinical discovery and clinical trials that led to the cysteine prodrug N-acetylcysteine being evaluated for the treatment of substance abuse and compulsive disorders.

Figures in this Article

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Place holder to copy figure label and caption
Figure.
Changes in Glutamatergic Synapses in the Nucleus Accumbens During Relapse After Long-term Use of Cocaine, Heroin, or Nicotine

The upper drawing is the control situation where glial glutamate uptake via glial glutamate transporter 1 (GLT1) is normal, thereby limiting access of synaptically released glutamate to extrasynaptic glutamate receptors, including metabotropic glutamate receptors (mGluRs) and N-methyl-d-aspartate (NMDA) receptors expressing the GluN2B subunit. After long-term drug use, glutamate uptake via GLT1 is downregulated. Thus, when an addict experiences drug-associated stimuli that can precipitate relapse, the corresponding release of glutamate more readily overflows the synaptic cleft to stimulate postsynaptic mGluR5 and NMDA receptors, which in turn increases AMPA signaling (elevated number of AMPA receptors) and synapse size, thereby potentiating synaptic activity. Supporting excessive presynaptic glutamate release, signaling via inhibitory presynaptic mGluR2 autoreceptors is reduced after long-term drug use. N-acetylcysteine restores GLT1, thereby normalizing synaptic potentiation by drug-associated stimuli and inhibiting relapse. Increases and decreases in signaling and glutamate uptake are indicated by larger or smaller arrowheads, respectively.

Graphic Jump Location

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 1

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
JAMAevidence.com


Addiction

brightcove.createExperiences();